Abdelfattah et al. developed an engineering platform (T-Switch) for the creation, modification, and high-throughput profiling of T cell receptors (TCRs) to desired targets, particularly self-antigens. T-Switch identified potent and specific candidate TCRs against a clinically relevant cancer self-target highly expressed in neuroblastoma and has potential for broader application in immunotherapy.

Large extrachromosomal DNAs are engineered using a CRISPR- and Cre–loxP-based approach and shown to drive cancer in mouse models, with potential applications in determining the role of oncogene a...